comparemela.com

Latest Breaking News On - Bionet asia - Page 1 : comparemela.com

Local jabs starved of funds

Domestic vaccine developers request funding

ChulaCov19 generates similar level of immunity as Pfizer, say researchers

ChulaCov19 generates similar level of immunity as Pfizer, say researchers
nationthailand.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationthailand.com Daily Mail and Mail on Sunday newspapers.

Thailand to start clinical trials on homemade Covid-19 vaccine; cases still high in Samut Sakhon on Saturday (Feb 20)

Thailand 08 Feb 2021 BANGKOK, Feb 20 (The Nation Thailand/ANN): The mRNA vaccine against the coronavirus developed by Chulalongkorn University of Thailand, is scheduled to enter the first stage of human trials soon, according to a university official. Kiat Ruxrungtham, who is in charge of the University s vaccine development project, confirmed the mRNA vaccine ChulaCov19 will be put on trial with humans in late April or early May, following satisfactory results of earlier trials with rats and macaques. If the human trials with the mRNA vaccine are successful, Thai company Bionet Asia will manufacture a range of one to five million doses of the vaccine by the end of this year, Kiat said.

Vaccine set to undergo human trials

Latest news: Anutin (second from left) holding a news conference to give an update on the progress of the ‘ChulaCov19’ vaccine in Bangkok. Reuters The country’s second domestically developed vaccine will soon undergo human trials, officials said, adding that the plan was to produce up to five million doses by the end of the year. The vaccine, developed by Thailand’s Chulalongkorn University, had success in trials in mice and monkeys and is due to be tested on humans in late April or early May, Kiat Ruxrungtham of the Chula Vaccine Research Center said. “By year-end we should have a production capacity of one to five million doses annually, ” Kiat told a news conference yesterday, adding this could later rise to about 20 million doses per year.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.